Samso is drawn to LinQ Minerals because the Company is demonstrating scale, thickness, and grade continuity within a recognised Tier-1 porphyry gold-copper province. Back-to-back long intercepts at the Dam deposit highlight a growing body of evidence that the Southern Zone hosts a coherent mineralised system capable of supporting further resource growth within an established mining district.

Viking Mines Ltd (ASX: VKA) has completed the acquisition of an extensive historical technical dataset covering its Linka Project in Nevada, USA (Figure 1). The dataset provides a high-resolution technical framework that supports faster geological understanding, early targeting, and validation drilling aimed at future JORC compliance. Samso’s coverage of Viking Mines reflects a focus on execution and technical progression rather than short-term news flow.

Samso is drawn to Singular Health because it is transitioning from proof-of-concept into contracted commercial deployment within the U.S. healthcare system. The Company is addressing a clearly defined inefficiency—medical imaging interoperability—through a regulatory-cleared, enterprise-ready platform with early validation from a large MSO partner.

Vitrafy Life Sciences Limited (ASX: VFY) released a market update on 15 January 2026 outlining a strategic commercial agreement with global animal reproduction leader IMV Technologies. The agreement positions Vitrafy’s cryopreservation technology within IMV’s global product and distribution platform, marking a material step in Vitrafy’s commercial execution strategy following Samso’s earlier IPO coverage of the Company.

Samso is drawn to Pioneer Minerals because it offers direct leverage to U.S. critical minerals policy themes through a diversified portfolio spanning tungsten, antimony, uranium, and lithium, all within Tier-1 mining jurisdictions. The combination of historical production, recent high-grade surface results, and near-term drilling catalysts positions PMM as a company transitioning from early-stage consolidation into active value creation.

Cyprium Metals Limited (ASX: CYM) has announced a A$41 million equity capital raising to accelerate regional exploration and production growth initiatives across its Paterson and Murchison copper portfolio. The funding supports the phased restart of the Nifty Copper Complex in Western Australia (Figure 1), where first cathode production is targeted for mid-2026, while also advancing studies for future expansion and satellite feed opportunities.

Samso is drawn to Pivotal Metals because the Company is applying systematic, district-scale geophysics to expand known high-grade mineral systems rather than relying on isolated drill targets. The combination of historic production, bonanza-grade gold intersections, and newly defined geophysical anomalies creates a technically coherent exploration narrative that is supported by infrastructure and jurisdictional advantages in Québec.

Firebird Metals Limited (ASX: FRB) has completed the installation and commissioning of its proprietary cathode active materials (CAM) equipment at its wholly owned China pilot plant, marking a key step in advancing lithium-manganese-rich (LMR) cathode development. The milestone supports Firebird’s vertically integrated ore-to-cathode strategy, with initial LMR CAM production scheduled to commence in February 2026 and customer sampling planned for the second half of 2026.

Samso is drawn to NeuroScientific because the Company is transitioning from early-stage development into real-world clinical validation. The Special Access Program outcomes represent a tangible inflection point, where clinical efficacy, regulatory engagement, and manufacturing readiness begin to converge around a scalable therapeutic platform.

ReNerve Limited has secured market registration approval in Malaysia for its NervAlign® Nerve Cuff, marking another regulatory milestone in the Company’s Asia-Pacific expansion strategy. The approval adds to existing clearances in Hong Kong and Thailand and follows a positive assessment of ReNerve’s clinical evaluation data. With an established US commercial base and a growing portfolio of nerve repair and tissue products.